HER2+VE Breast Cancer By Chetan Deshmukh
SESSION 2 : HER2+VE BREAST CANCER
Chairpersons :
Avinash Deo, Vivek Agarwala, Amul Kapoor
Reviewer :
Chetan Deshmukh
1. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the
presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG
2012-03)
Author: Mette S.
Citation: ASCO Abstract 507 Journal of Clinical Oncology 35, no. 15_suppl (May
2017) 507-507
2. Phase III study of Lapatinib (L) plus Trastuzumab (T) and Aromatase Inhibitor (AI) vs
T+AI vs L+AI in Postmenopausal Women (PMW) with HER2+, HR+ Metastatic Breast
Cancer (MBC): Alternative
Author: William John Gradishar
Citation: ASCO Abstract 1004 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)
1004-1004
3. Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± Pertuzumab
(P) vs. Trastuzumab + Taxane (HT) treatment of HER2-positive MBC: Final Overall
Survival (OS) and safety from MARIANNE
Author: Edith A. Perez
Citation: ASCO ABSTRACT 1003 Journal of Clinical Oncology 35, no. 15_suppl (May
2017) 1003-1003